BOSTON, Jan. 17 /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar) today issued a review on Arbios Systems, Inc. (NASDAQ:ABOS)(OTC:ABOS) Bulletin Board entitled "Developing Multiple Products to Meet the Unmet Medical Needs of Patients in Liver Crisis". Arbios Systems, Inc is a pure play in the development of treatments for patients suffering from acute-on-chronic or acute liver failure. At present, no direct treatment for liver failure is available. ABOS.OB has two innovative, proprietary liver-assist product candidates in clinical development: SEPET(TM), a proprietary system that selectively filters the blood for patients with acute- on-chronic liver failure, currently in a Phase 1/2 feasibility study with positive interim data; and HepatAssist(TM), a unique bioartificial liver system that fully replaces human liver function, in patients with acute liver failure, currently awaiting to re-start Phase 3 clinical development. The analyst research review is available on Scimitar's website: http://www.scimitarequity.com/. Scimitar Equity Research, Inc. provides sponsored equity research of the healthcare industry for the institutional and investment communities. We certify that all the views expressed in this review, accurately reflect our personal views about ABOS.OB (Nasdaq; OTC Bulletin Board: BB) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures. CONTACT: Scimitar Equity Research, Inc. Henry W. McCusker Director of Research phone: (617) 559-1080 fax: (617) 559-1083 e-mail: DATASOURCE: Scimitar Equity Research, Inc CONTACT: Henry W. McCusker, Director of Research for Scimitar Equity Research, Inc., +1-617-559-1080, FAX +1-617-559-1083, Web site: http://www.scimitarequity.com/

Copyright